Innovating.works Conecta tu I+D

SECRET: Exploring the therapeutic potential of perinatal cell SECRETomes Over the past two decades, cells isolated from human perinatal (or birth-associated) tissues (amniotic membrane, umbilical cord tissue and c...
2024-07-16 - 2028-08-31 | Financiado

AUREUS: wAll teichoic acids as immUnogenic and conseRved altErnative targets for therapies versUs S. aureus The AUREUS doctoral network meets the increasing need of a highly qualified work force to counteract multidrug-resistant S. aureus infection...
2024-07-01 - 2029-01-31 | Financiado

LIVERAIM: A Biomarker Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Thera... INNOVATION ACTA SRL participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-03-single-stage Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems...
2023-11-27 - 2030-02-28 | Financiado

GUIDE.MRD: GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD INNOVATION ACTA SRL participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved o...
2023-05-17 - 2028-04-30 | Financiado

IMMUTOL: ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED... INNOVATION ACTA SRL participó en un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the ca...
2023-04-14 - 2027-04-30 | Financiado

PROTO: PROTO - Advanced PeRsOnalized Therapies for Osteoarthritis – TACKLING INFLAMMATION TO IMPROVE PATIEN... INNOVATION ACTA SRL participó en un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-02 Osteoarthritis (OA) is the most common form of arthritis worldwide. Chronic low-grade inflammation in the articular environment causes carti...
2022-11-17 - 2027-12-31 | Financiado

T-FITNESS: FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS INNOVATION ACTA SRL participó en un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 Cell and gene therapies offer a massive paradigm shift from current treatment options and hold the potential to cure previously untreatable...
2022-07-08 - 2026-08-31 | Financiado

geneTIGA: Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome edit... INNOVATION ACTA SRL participó en un HORIZON EUROPE: HORIZON-HLTH-2021-TOOL-06 "There is an increasing prevalence of chronic diseases caused by undesired immune reactions (>10%) with high burden for the both patients (c...
2022-05-23 - 2026-06-30 | Financiado

LiverScreen: Screening for liver fibrosis population based study across European countries INNOVATION ACTA SRL participó en un H2020: H2020-SC1-BHC-2018-2020 Liver cirrhosis is a very common and severe chronic disease, responsible for high morbidity, impaired quality of life, major healthcare cost...
2019-12-12 - 2025-06-30 | Financiado

HDM-FUN: Host directed medicine in invasive fungal infection INNOVATION ACTA SRL participó en un H2020: H2020-SC1-BHC-2018-2020 Despite novel treatment options and development of diagnostic tools invasive fungal infections (IFI) are still associated with an unacceptab...
2019-12-06 - 2024-12-31 | Financiado

RESTORE: RESTORE Health by Advanced Therapies Advanced Therapy Medicinal Products and Biologized Medical Dev... INNOVATION ACTA SRL participó en un H2020: H2020-FETFLAG-2018-2020 Recently, a new class of living drugs has been developed – Advanced Therapies which aim to transform the current focus of treatment of disea...
2019-02-08 - 2020-07-31 | Financiado

NECESSITY: NEw Clinical Endpoints in primary Sjögren s Syndrome an Interventional Trial based on stratifYing p... INNOVATION ACTA SRL participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease (AID) involving 0.5 to 3/1000 persons. The disease affects exocrine glands...
2018-12-18 - 2025-12-31 | Financiado

RESHAPE: Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next Generation regulatory T ce... INNOVATION ACTA SRL participó en un H2020: H2020-SC1-BHC-2018-2020 Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in i...
2018-11-21 - 2024-12-31 | Financiado

INTEGRATA: Integrating chemical and biological approaches to target NAD production and signaling in cancer INNOVATION ACTA SRL participó en un H2020: H2020-MSCA-ITN-2018 Deregulated nicotinamide adenine dinucleotide (NAD) biosynthesis and signaling underlies many aspects of carcinogenesis. NAD biosynthetic en...
2018-09-13 - 2023-04-30 | Financiado

HIPGEN: Placenta expanded adherent stromal cells PLX PAD as an innovative therapy for improving recovery a... INNOVATION ACTA SRL participó en un H2020: H2020-SC1-2016-2017 Aim of the HIPGEN project is to develop the first cell therapy to improve functional recovery following hip fracture arthroplasty. Hip fract...
2017-11-21 - 2022-09-30 | Financiado

LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS INNOVATION ACTA SRL participó en un H2020: H2020-SC1-2016-2017 Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact...
2016-12-09 - 2023-02-28 | Financiado

PACE: A multicenter phase IIb study using HLA unmatched allogeneic placenta derived stromal cells PLX PAD... INNOVATION ACTA SRL participó en un H2020: H2020-SC1-2016-2017 PACE aims to transform the treatment of patients suffering from critical limb ischemia (CLI), a disease with high medical need, because of l...
2016-12-01 - 2021-12-31 | Financiado